The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials

The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials

TRAIL (tumor-necrosis factor related apoptosis-inducing ligand, CD253) and its death receptors TRAIL-R1 and TRAIL-R2 selectively trigger the apoptotic cell death in tumor cells. For that reason, TRAIL has been extensively studied as a target of cancer therapy. In spite of the promising preclinical o...

Full description

Bibliographic Details
Main Authors: Martin Snajdauf, Klara Havlova, Jiri Vachtenheim, Andrej Ozaniak, Robert Lischke, Jirina Bartunkova, Daniel Smrz, Zuzana Strizova
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Molecular Biosciences
Subjects:
TRAIL clinical trials
recombinant TRAIL
TRAIL-receptor agonists
cancer
dulanermin
mapatumumab
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.628332/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2021.628332/full

Similar Items